Ortec Names Marc Jacobs as Vice President of Product Development.Business Editors & Health/Medical Writers BIOWIRE2K NEW YORK--(BW HealthWire)--November 22, 2000 Ortec International, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ORTC ORTC Old Republic Title Company ORTC Operational Readiness Training Complex ) announced today that Marc L. Jacobs, formerly of Bristol-Myers Squibb has joined Ortec as its Vice President of Product Development. Mr. Jacobs brings to Ortec over 25 years of industry experience in research and product development. His primary responsibility at Ortec will be to direct the scale-up of manufacturing processes in preparation for product launch. Prior to joining Ortec, Mr. Jacobs spent 10 years at Bristol-Myers Squibb's Convatec Division where he led an 80-member organization and served in the capacities of Director of Ostomy Product Development, Vice President of Chronic Care R & D, and Vice President of Applied Research. In those capacities, Mr. Jacobs was responsible for developing technical strategy and implementing product development activities from concept feasibility through product launch. Prior to his position at Bristol-Myers Squibb, Mr. Jacobs served as Vice President of R & D and Senior Technical Officer at Kingston Technologies, Inc., a developer of hydrogel hy·dro·gel n. A colloidal gel in which the particles are dispersed in water. hydrogel a gel that contains water. hydrogel Wound care A polymer absorptive wound dressing. See Dressing. material technology for medical devices and cosmetic products. In this capacity, Mr. Jacobs also managed and planned the construction and transition into the company's GMP GMP (guanosine monophosphate): see guanine. manufacturing facility, wrote its first regulatory submission, and obtained FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for its novel medical device. Previous to his duties at Kingston Technologies, Mr. Jacobs served as Director of Product Development at Johnson and Johnson's Extracorporeal extracorporeal /ex·tra·cor·po·re·al/ (-kor-por´e-al) situated or occurring outside the body. ex·tra·cor·po·re·al adj. Situated or occurring outside the body. Division, where he attained the position of Director of Product Development providing technical support to its global manufacturing and marketing operations. Mr. Jacobs holds a Bachelors in Science from Brown University and a Masters in Science with concentration in Biomaterials from the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. . Commenting on Ortec's new hire, Steven Katz, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Ortec, said, "We are delighted that Marc Jacobs has joined us and look forward to his contributions as we prepare for our transition to commercialization." About Ortec International, Inc. Ortec International, Inc. is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. Ortec's current focus is the application of its Composite Cultured Skin composite cultured skin Dermatology A skin substitute used to cover burn wounds and epidermolysis bullosa. See Artificial skin. (CCS (1) (Common Channel Signaling) A communications system in which one channel is used for signaling and different channels are used for voice/data transmission. Signaling System 7 (SS7) is a CCS system, also known as CCS7. See SS7. ) product to heal chronic and acute wounds. Ortec believes that its platform technology may extend to the development of other human tissue, such as tendons, ligaments, cartilage, bone, muscle and blood vessels. Certain statements made in this news release that express the belief, potential anticipation or expectation, as well as other statements which are not historical fact, and statements relating to the clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality and performance insofar as they may apply prospectively, are "forward looking" statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in this news release or in other "forward looking" statements presented by management. Factors that might cause such a difference include, but are not limited to, development by the Company's competitors of new technologies or products that are more effective than the Company's, risks of failure of clinical trials, dependence on and retention of key personnel, protection of proprietary technology, compliance with U.S. Food and Drug Administration regulations, continued availability of raw material for the Company's products, availability of product liability insurance in the event of commercialization of the Company's products, ability to effect transition from pilot-scale manufacturing to large-scale commercial production of products, uncertainty as to the availability of additional capital on acceptable terms, if at all, and the demand for the Company's products, if and when commercially available. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion